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Triple-negative breast cancer (TNBC) is a highly heterogeneous disease with multiple, distinct molecular subtypes that exhibit
unique transcriptional programs and clinical progression trajectories. Despite knowledge of the molecular heterogeneity of the
disease, most patients are limited to generic, indiscriminate treatment options: cytotoxic chemotherapy, surgery, and radiation.
To identify new intervention targets in TNBC, we used large-scale, loss-of-function screening to identify molecular vulnerabili-
ties among different oncogenomic backgrounds. This strategy returned salt inducible kinase 2 (SIK2) as essential for TNBC sur-
vival. Genetic or pharmacological inhibition of SIK2 leads to increased autophagic flux in both normal-immortalized and tu-
mor-derived cell lines. However, this activity causes cell death selectively in breast cancer cells and is biased toward the claudin-
low subtype. Depletion of ATG5, which is essential for autophagic vesicle formation, rescued the loss of viability following SIK2
inhibition. Importantly, we find that SIK2 is essential for TNBC tumor growth in vivo. Taken together, these findings indicate
that claudin-low tumor cells rely on SIK2 to restrain maladaptive autophagic activation. Inhibition of SIK2 therefore presents
itself as an intervention opportunity to reactivate this tumor suppressor mechanism.
Breast cancer is an extremely heterogeneous disease that is clas-sified by the presence of estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2
(HER2). Cases where 1% of cells express ER, PR, or HER2 are
considered triple-negative breast cancer (TNBC) (1). These mo-
lecular markers can serve as a critical stratification tool for tailor-
ing effective therapies to sensitive patients. For example, anties-
trogens such as tamoxifen are highly effective in ER-positive
patients, and HER2-positive tumors are responsive to trastu-
zumab (2, 3). Conversely, TNBC tumors lack these targetable pro-
teins, limiting first-line treatment to a combination of radiation
and chemotherapy. This approach has changed little over the last
20 years and is characterized by high toxicity and frequent relapse
of chemorefractory disease (4). Furthermore, levels of overall and
disease-free survival in TNBC are significantly worse than those of
other subgroups of breast cancer (5). Thus, for TNBC there is a
dire need for less toxic therapies that target the major fulcrums
supporting tumor cell survival.
In addition to clinical and pathologicalmarkers, extensive gene
expression profiling efforts by a number of groups have identified
multiple intrinsic molecular subtypes within breast cancer. These
subtypes include luminal A and B, which comprise themajority of
ER- and PR-positive cases, as well a HER2-enriched clade. Impor-
tantly, this analysis has revealed substantial heterogeneity within
TNBC. Broadly, TNBC can be subclassified into 2 intrinsic sub-
types, basal like and claudin low, but up to 6 additional subclasses
have been identified (6–9). Significantly, these groups can be
aligned with sensitivity to specific therapies and overall patient
survival (4, 6–8, 10). A number of recent studies have indicated
that the spectrum of subtypes found in vivo is represented among
existing tumor-derived cell lines (8, 9, 11). Thus, these cell lines
offer amodel system that faithfully recapitulates the heterogeneity
of the human disease and could reveal subtype-selective vulnera-
bilities.
Here, we have applied genome-scale loss-of-function screen-
ing in both the claudin-low and basal-like subtypes to discover
molecular targets for TNBC. We find that salt-inducible kinase 2
(SIK2) is essential for survival, particularly in the claudin-low sub-
type. There are 3 salt-inducible kinases (SIK1, SIK2, and SIK3),
which are best characterized as regulators of gluconeogenesis.
Upon glucagon stimulation, protein kinase A (PKA) inactivates
SIK, thereby relieving inhibitory phosphorylation of CRCT2/3,
which then cooperates with CREB to activate gluconeogenic tran-
scriptional programs (12, 13). Importantly, tissue-specific dele-
tions of SIK proteins in mice can lead to altered glucose and lipid
metabolism (14–16). Additional findings have also implicated
SIK2 proteins in modulating autophagy and inflammatory re-
sponses (17–21). With respect to cancer, two reports have indi-
cated that SIK2 is essential for centrosome splitting and mitotic
progression, and SIK1 loss can inhibit anoikis and promotes me-
tastases (22–24).
The contribution of SIKs to biological processes that are often
misregulated in human disease has driven efforts to develop
small-molecule inhibitors. SIKs aremembers of the AMPK family
but are unique in this group, as they contain a low-stearic-hin-
drance residue (threonine) at their gatekeeper site (25, 26). This
small residue creates an extended hydrophobic pocket that en-
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hances flexibility and, thus, autoactivation of the kinase (27, 28).
This pocket can also selectively accommodate small-molecule in-
hibitors that would otherwise be occluded by a bulky side chain.
For example, AMPK contains a methionine at this residue, sug-
gesting that SIK inhibitors would haveminimal off-target activity.
We find that in TNBC, SIK2 functions to restrict autophagy,
which in the claudin-low subtype is essential for viability. The
contribution of autophagy to tumorigenesis has been somewhat
contentious. Autophagy is reported to function both as a tumor
suppressor mechanism as well as a survival mechanism, depend-
ing on the tumor cell context (29).With respect to TNBC, a recent
study found that a subset of ER-negative tumors exhibit down-
regulation of the critical autophagic protein and tumor suppres-
sor, beclin-1. These patients exhibited poorer overall survival,
suggesting that restriction of autophagy in receptor-negative, ad-
vanced disease promotes tumor survival (30). Our findings sug-
gest inhibition of SIK2 could release this brake on autophagy and
thus presents a therapeutic strategy in the claudin-low subtype.
MATERIALS AND METHODS
Cell lines. Cell lines were obtained from the ATCC with the following
exceptions: SUM159, SUM149, and HuMEC (Charles Perou, University
of North Carolina at Chapel Hill [UNC]); HME50-hTERT (Jerry Shay,
UT Southwestern [UTSW]); WHIM12 (Matthew Ellis, Baylor College of
Medicine); HCC1806, HCC1143, and HCC1395 (Gray Pearson, UTSW);
HCC1937, HCC1954, HCC38, U2OS, and U2OS-GFP-LC3 (Michael
White, UTSW); 293T,MDA-MB-231, andHs578t (Gary Johnson, UNC);
and MDA-MB-157 and HCC1569 (Ganesh Raj, UTSW). All cell lines
were cultured in the provider’s recommended medium. Cell lines were
authenticated using short tandem repeat analysis (STR).
Antibodies and reagents. The following antibodies were used for im-
munoblotting: SIK2 (6919; 1:1,000), LC3B (3868; 1:1,000), total ULK1
(8054; 1:1,000), phospho-ULK1 (serine 555) (5869; 1:1,000), p62 (8025;
1:1,000), CRTC2 (3926; 1:1,000), and ATG5 (1:1,000) (all from Cell Sig-
naling Technologies); extracellular signal-related kinase 1/2 (ERK1/2)
(sc-93; 1:1,000; Santa Cruz); SIK2 (636702; 1:1,000; BioLegend); phos-
pho-CRTC2 (serine 275) (1:1,000; gift from Olga Goransson, Lund Uni-
versity); phospho-histone 3B (serine 10) (1:200; Millipore); and pericen-
trin (1:1,000; AbCam). Antibodies used for immunofluorescence were V5
(Life Technologies) and p62 (sc-28359; 1:100; Santa Cruz). The SIK2 in-
hibitor ARN-3236 was obtained from Arrien Pharmaceuticals, Inc. HG-
9-91-01 was obtained from Fisher Scientific. CellTiter-Glo (CTG) was
purchased fromPromega. Lipofectamine RNAiMAXwas purchased from
Thermo Fisher Technologies. Opti-MEM and Hoechst 3342, trihydro-
chloride, trihydrate were obtained from Thermo Fisher Scientific. Pacli-
taxel was obtained from Tocris Bioscience.
Expression plasmids and mutagenesis. Human SIK2 (clone
IOH45349) was obtained in pENTR221 from the Ultimate ORF (open
reading frame) collection from Thermo Fisher Technologies (housed at
UTSW). pENTR221 SIK2 was cloned into pLX302 using the Gateway
cloning system (ThermoFisher Scientific). Kinase-dead SIK2 (K49M)was
generated using site-directed mutagenesis using the following primers:
forward, ACCAAGACGGAGGTGGCAATAATGATAATCGATAAGTC
TCAGC; reverse, GCTGAGACTTATCGATTATCATTATTGCCACCTC
CGTCTTGGT.
Viral packaging plasmids pCMV-dr8.91 and pCMV-VSV-G were a
gift from Michael White (UTSW). pCDH-GFP-LC3 (Channing Der,
UNC) was used for GFP-LC3 SUM159 cells. For SIK2 short hairpin
RNA (shRNA), PLKO.1 SIK2 shRNA clones TRCN0000196955 and
TRCN0000037494 and PLKO.1 nonsilencing control (from the Broad
Institute RNAi Consortium) were purchased from Sigma.
Cell viability assays. Cells were reverse transfected in 96-well format.
One hundred twenty hours postplating, luminescence values were read
following addition of 15l of Cell Titer-Glo on a PHERAstar Plus (BMG)
plate reader. Where indicated, cells were exposed to a final concentration
of 1 nM paclitaxel 48 h postplating. For ARN-3236 treatment, cells were
plated and simultaneously treated with 2 M ARN-3236 or vehicle con-
trol. Forty-eight hours later, cells were treated again with 2 M ARN-
3236. Viability readings were taken 96 h after plating. For HG-9-91-01
treatment, cells were treated as described above with 1 M the inhibitor.
siRNA transfections. Short interfering RNA (siRNA) pools were ob-
tained from GE Healthcare (M-004778-03; siGENOME siRNA) or Sigma
(SASI_Hs01_00054682, SASI_Hs01_00054683, and SASI_Hs01_00054684;
Mission). Control siRNA (siCTRL) used was a nontargeting control (D-
001206-14 and D-001210-05; GE Healthcare) or siRNA targeting
FNDC3B (MU-017856-00; GEHealthcare), which was innocuous in pan-
genomic screening. Cells were reverse transfectedwith 8.6 pmol siRNA for
CTG and 4.3 pmol siRNAs for all other assays. A toxic siRNA, UBB (M-
013382-01; GE Healthcare), was used to monitor transfection efficiency.
CTG values for UBB transfection must result in viability loss of 90%
compared to the control transfected cells for inclusion.
Pangenomic siRNA screen and data processing. An siGENOME
SMARTpool siRNA library targeting 18,171 genes was purchased from
GE Healthcare in 96-well plate format. siRNA pools (4.3 pmol) were
transfected into cells using Lipofectamine RNAiMax solution. Forty-eight
hours later, cells (SUM159, SUM149, HCC1806, and WHIM12) were
treated with either vehicle or 1 nM paclitaxel. Ninety-six hours postplat-
ing, cell viability wasmeasured using CellTiter-Glo according to theman-
ufacturer’s protocol, modified to use 15 l per well. Measurements were
made with a PHERAstar Plus (BMG) plate reader. Individual values were
normalized to the medians of their respective rows. The normalized pa-
clitaxel-treated values were divided by the untreated values to derive a
synthetic lethal value. Z-scores, based on the means and standard devia-
tions from each plate, then were calculated for each gene for both direct
(no paclitaxel) and synthetic behavior. See Table S1 in the supplemental
material for Z-scores and normalized viability scores.
Lentiviral infections. Lentivirus was produced through cotransfec-
tion ofHEK293T cells with 3g of viral expression vector, 3g of pCMV-
dr8.91 packing vector, and 300ng of pCMV-VSV-G envelope vector using
Fugene according to themanufacturer’s protocol. Virus-conditionedme-
dium was harvested, passed through 0.45-m filters, and then used to
infect target cells in the presence of 10 g/ml Sequa-brene. Following
infection, stable populations were selected using appropriate antibiotics.
For shSIK2, knockdown was validated 2 days following infection (by
quantitative PCR [qPCR] and immunoblotting), and downstream assays
were performed without selection.
Colony formation assay. One hundred twenty hours after siRNA
transfection, cells deemed viable by trypan blue exclusion assay were re-
plated at limiting dilution in 6-well format. Cells were fed twice weekly
until control colonies began to merge. Samples were fixed with 3.7%
formaldehyde and stained with Giemsa.
Soft-agar assays. For siSIK2 soft-agar assays, SUM159 cells were re-
verse transfected with 10 pmol of siRNA. Seventy-two hours posttrans-
fection, cells were resuspended in 0.375% Bacto agar in complete me-
dium, and 2 103 viable cells were plated over a layer of solidified 0.7%
Bacto agar in a 24-well dish. Cells were fed once weekly for 2 weeks and
then stained with Giemsa. For SUM159 shSIK2 soft-agar assays, SUM159
cells stably expressing the indicated shRNAs were resuspended in 0.375%
Bacto agar in completemedium, and 2 103 cells were plated over a layer
of solidified 0.7% Bacto agar in 24-well dishes. Colonies were fed once a
week for 2 weeks and then stained with Giemsa. For ARN-3236 soft-agar
assays, SUM159 cells were resuspended in 0.375% Bacto agar in complete
medium, and 2 103 cells were plated over a layer of solidified 0.7%Bacto
agar in 24-well dishes. Cells were treated with 1 M ARN-3236 each day
for 9 days. Cells were fed once with 2 serum on the sixth day. The cells
were stained with 0.05% crystal violet in 10% ethanol. All soft-agar assays
were manually counted using a Leica M7z stereoscope.
Gene expression. Total RNA was isolated using an RNA isolation kit
(Sigma) and reverse transcribed using the high-capacity cDNA reverse
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transfection kit (Life Technologies) according to the manufacturer’s in-
structions. An Applied Biosystems real-time PCR system and TaqMan
real-time PCR gene expression assays were used to measure gene expres-
sion for SIK2 (Hs01568566_m1) and RPL27 (Hs03044961_g1). Expres-
sion values relative to those of RPL27 were calculated using the compar-
ative threshold cycle (CT) method.
Immunoblotting. Whole-cell lysates were prepared in 2 Laemmli
sample buffer and resolved using SDS-PAGE. Gels were transferred to
Immobilon polyvinylidene difluoride (PVDF;Millipore), blocked inTris-
buffered saline containing 0.1% Tween 20 (TBST) and either 5% nonfat
dry milk or bovine serum albumin (BSA), and incubated with the indi-
cated primary antibodies overnight. After washes in TBST, appropriate
horseradish peroxidase (HRP)-coupled secondary antibodies (Jackson
ImmunoResearch) were used for chemiluminescence. ImageJ was used to
quantitate band intensity.
Immunofluorescence.Cells plated on glass coverslips were fixed with
3.7% formaldehyde and then permeabilized with 0.5% Triton X-100 for
10 min. Cells were blocked and washed in 1% BSA, 0.1% Tween 20 in 1
phosphate-buffered saline (PBTA). Cells were incubated with primary
antibodies for 1 h, followed by three washes in PBTA. Coverslips were
then incubated with Alexa Fluor-conjugated secondary antibodies
(Thermo Fisher Scientific) for 30 min, followed by 3 washes in PBTA and
a wash in H2O. Prolong Gold antifade reagent with 4=,6-diamidino-2-
phenylindole (DAPI; Thermo Fisher Scientific) was used to mount slips
on glass slides. Imageswere acquired on either a LeicaDM55000Bupright
microscope, a Zeiss Axio Imager upright microscope, or a Zeiss LSM510
confocal microscope.
FACS. U2OS GFP-LC3 cells were reverse transfected with 10 pmol of
siRNA. Sixteen hours prior to fluorescence-activated cell sorting (FACS)
analysis, cells were treated with either vehicle or 50 M Cq. Seventy-two
hours posttransfection, cells were trypsinized, washed twicewith PBS, and
fixedwith ethanol (EtOH) for 30min at 4°C. Cells were thenwashed twice
with PBS and sorted by green fluorescent protein (GFP) fluorescence with
a BeckmanCoulter CyAnADPusing Summit 4.3 and analyzedwithMod-
Fit 4.0 DNA analysis software. A minimum of 1.0 104 events was used
for analysis.
shSIK2 xenograft injections. A total of 8  105 SUM159 cells stably
expressing pLKO.1 shSIK2 or a nontargeting control hairpin (200 l)
were injected in the right flank of NOD.cg-PRKDCSCIDIl2rgtm1Wjl/SzJ
(NSG) female mice, aged 4 to 6 weeks. Tumors were measured twice
weekly using a digital caliper, and volume (V) was calculated using the
following equation: V (length of the longest side) (length of the side
perpendicular to the longest side)2/(/6). According to IACUC guide-
lines, mice bearing tumors greater than 2,000 mm3 or exhibiting signifi-
cantly diminished health were sacrificed. Tumors were surgically re-
moved, weighed, and formalin fixed for 48 h. All studies were conducted
in accordance with a UTSW IACUC-approved protocol.
RESULTS
To identify targetable vulnerabilities in TNBC, we implemented a
tiered siRNA screening strategy to enrich for concordant re-
sponses among diverse oncogenomic backgrounds found in cell
models of this disease. Given that the majority of TNBC tumors
are classified as either claudin-low or basal-like subtype, we used
cell lines representing both of these subtypes to account for biased
vulnerabilities (7–9, 11). In the first tier of the analysis, we per-
formed a genome-wide siRNA toxicity screen in the SUM159
claudin-low cell line (Fig. 1A and B; see also Table S1 in the sup-
plemental material). As paclitaxel is a first-line chemotherapeutic
in TNBC, we performed a 2-condition screen to assess conse-
quences of gene depletion alone and in the presence of an innoc-
uous dose (1 nM) of this agent (Fig. 1C). Here, we identified 30
candidate targets whose viability ratio (paclitaxel treated/un-
treated) was 5 standard deviations below the means (Fig. 1D).
These 30 siRNAs were then evaluated for their activity in the
WHIM12 (claudin-low), HCC1806 (basal-like), and SUM149
(basal-like) cell lines in the presence and absence of paclitaxel
(Fig. 1E). This strategy identified SUM159-idiosyncratic siRNAs
(NCOA6, LGR8, andMYO3A) as well as siRNAs with broad pen-
etrance under all conditions tested (RBBP9, GLB1L2, KERA, and
NNAT). We focused on siRNAs exhibiting selectivity within the
panel, reasoning that these would be the least likely to target
housekeeping functions in both tumor and normal cells. Among
these, we identified salt-inducible kinase 2 (SIK2), whose deple-
tion led to a dramatic loss in viability of SUM159 cells, moderate
defects in WHIM12 and HCC1806, and no effect on SUM149
cells. This phenotype was observed with 2 independent siRNAs,
both of which led to a strong reduction of SIK2 mRNA and pro-
tein levels (Fig. 1F). Knowledge of SIK2’s contribution to tumor-
igenesis is limited to only two reports, which suggest an oncogenic
function of this kinase in ovarian and prostate cancers (22, 23).
Importantly, small-molecule SIK2 inhibitors are under active de-
velopment to treat a number of human diseases, making this an
actionable target in the near future (17, 31). Given the relative
dearth of information on this therapeutically tractable protein, we
focused follow-up efforts on its function in TNBC.
We further assessed the specificity of the SIK2 dependency in a
panel of TNBC cell lines composed of 8 claudin-low, 8 basal-like,
and 2 normal-immortalized cell lines (Fig. 2A). Here, 6 of the 8
claudin-low cell lines exhibited a loss of viability following siSIK2
transfection with 2 independent siRNAs. In contrast, only 1 of the
8 basal-like cell lines, HCC1806, appeared sensitive. Notably, this
basal-like outlier is the only cell line derived from a primary acan-
tholytic squamous cell carcinoma, a pathology distinct from that
of ductal carcinomas.We observedminimal defects in the normal
setting, indicating that the dependency on SIK2 was unique to the
tumorigenic state. The viability decrease in the siSIK2-sensitive
lines was not complete, as 30 to 40% of the population remained.
Thus, we replated SIK2-depleted cells at limiting dilution to assess
growth capacity of the residual population. Here, we observed a
dramatic reduction in colony formation, suggesting that the ma-
jority of remaining cells were not viable following siSIK2 transfec-
tion (Fig. 2B). Furthermore, SIK2-depleted cells exhibited atten-
uated anchorage-independent growth, suggesting that SIK2 is
required for tumorigenicity in TNBC (Fig. 2C).
We next evaluated the consequences of pharmacological inhi-
bition of SIK2 on viability in TNBC. ARN-3236 is a recently de-
veloped ATP competitive inhibitor of SIK that associates with the
hinge region. In vitro, ARN-3236 exhibits a 50% inhibitory con-
centration (IC50) of 1 nM toward SIK2 (21.63 and 6.63 nM for
SIK1 and SIK3, respectively) (17). To credential the effects of
ARN-3236 on intact TNBC cells, we assayed its effects on phos-
phorylation of the well-characterized SIK2 substrate TORC2
(CRTC2) (12, 13, 25). Exposure of SUM159 cells to ARN-3236 for
6 h led to a reduction in phosphorylation of CRTC2, indicating
inhibition of the SIK2 kinase (Fig. 2D) (12, 13).We treated a panel
of TNBC cell lines with ARN-3236 and observed a decrease
of50% viability in two of the siSIK2-sensitive cell lines but lim-
ited defects in the siSIK2-resistant cell lines (Fig. 2E). The viability
defect was also observed with a structurally distinct pan-SIK in-
hibitor, HG-9-91-01 (Fig. 2E) (31). Exposure of SUM159 cells to
ARN-3236 also attenuated growth in soft agar, phenocopying the
defect observed with siSIK2 (Fig. 2C and F). Taken together, these
findings suggest that SIK2 is essential for viability and tumorige-
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nicity, particularly in the claudin-low subtype of TNBC, and phar-
macological inhibition of this kinase is sufficient to reduce tumor
growth.
A number of recent reports have implicated SIK2 in the mod-
ulation of autophagy (18, 21). Also, the expression of the tumor
suppressor beclin-1 is lost in a subset of TNBC, suggesting that
autophagy is altered in a subset of TNBC tumors (30). Thus, we
examined the consequences of SIK2 depletion on accumulation of
microtubule-associated protein light chain 3 (LC3), which associ-
ateswith the autophagosomalmembrane and can be used tomon-
itor autophagic activity. Depletion of SIK2 led to a pronounced
decrease in both LC3-I and -II accumulation in tumor and normal
cell lines, irrespective of the effect of SIK2 on viability (Fig. 3A).
Similarly, accumulation of p62, an adaptor protein found on au-
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tophagic vesicles, was also decreased in SIK2-depleted cells (Fig.
3B). The reduction of LC3 and p62 is consistent with enhanced
vesicle flux through the pathway. To further evaluate this possi-
bility, we assayed the activation of ULK1, which is phosphorylated
on Ser555 by AMPK kinase as an initial step in autophagosome
formation (32–34). Depletion of SIK2 led to a robust increase in
phosphorylation on Ser555, indicating that autophagy was acti-
vated (Fig. 3C). We then stably expressed GFP-LC3 in SUM159
cells (SUM159-GFP-LC3) to monitor the accumulation of au-
tophagic vesicles in single cells. We exposed cells to chloroquine
(Cq), a lysosomotropic agent that leads to vesicle accumulation by
preventing autophagosomal maturation. Under these conditions,
SIK2 depletion led to a significant increase in the accumulation of
GFP-LC3-positive vesicles (Fig. 3D and E). FACS analysis in
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U20S-GFP-LC3 cells revealed that depletion of SIK2 enhanced
GFP-LC3 accumulation, which was increased further upon Cq
exposure (see Fig. S1A in the supplemental material). Notably,
U20S cells also exhibited a reduction in viability upon depletion of
SIK2 (see Fig. S1B). We also used p62 to monitor endogenous
autophagosomes and found that SIK2 depletion and exposure to
Cq led to an enhanced accumulation of p62-positive puncta (Fig.
3F and G).
To assess whether pharmacological inhibition of SIK2 pheno-
copied the siRNAphenotype, we exposed SUM159-GFP-LC3 cells
to ARN-3236 in the presence of Cq. Here, we observed a time-
dependent accumulation of GFP-LC3 vesicles, similar to the
siRNA phenotype (Fig. 3H and I). We next asked whether the
kinase activity was required for the observed changes in flux by
stably overexpressing a kinase-dead mutant of SIK2 (K49M).
Upon exposure to Cq, we observed an increase in autophagic flux,
indicating that the kinase-dead mutant functions in a dominant-
negative fashion (Fig. 3J). These data indicate that SIK2 restrains
autophagy in TNBC, which in a specific subset of tumors is essen-
tial for survival.
We next evaluated whether the activation of autophagy upon
SIK2 loss was responsible for the reduction in tumor cell viability.
To do this, we performed an epistasis experiment in which au-
tophagic vesicle formation was inhibited by depletion of ATG5, a
key lipidation protein essential for the first steps in vesicle forma-
tion. In SUM159 cells, loss of ATG5 alone reduced GFP-LC3 ves-
icle accumulation and enhanced LC3-I, which is not associated
with autophagosomes (Fig. 4A). Importantly, when SIK2 and
ATG5 were codepleted, the ATG5 phenotype dominated, as we
observed minimal vesicle formation and a stabilization of LC3-I
(Fig. 4A and B). Moreover, codepletion of ATG5 rescued the loss
of viability observed upon depletion of SIK2 alone (Fig. 4C and
D). These data indicate that inhibition of SIK2 leads to excessive
autophagy, which in certain TNBC settings results in cell death.
Findings thus far suggest that SIK2 is essential for viability, and
its inhibition could be an antitumor strategy. Thus, we next as-
sessed whether inhibition of SIK2 in vivo would reduce tumor
growth (30). To test this possibility, we used shRNA to reduce
SIK2 mRNA and protein in SUM159 cells (Fig. 4E). These cells
were attenuated in their capacity to form colonies in soft-agar
assays,mimicking the phenotypes observedwith siSIK2 andARN-
3236 (Fig. 4F). Immediately following knockdown, these cells
were implanted into the flanks of NSG mice and tumor growth
was monitored for 6 weeks. Tumor initiation in shSIK2 tumors
was significantly decreased and shSIK2 tumors weremuch smaller
than those in the control group (Fig. 4G), suggesting that SIK2 is
essential for tumorigenesis in vivo. Collectively, these results sug-
gest that SIK2 functions in breast tumor and normal cells to re-
strain autophagic flux. In a subset of TNBC this function is essen-
tial for survival, and releasing this brake leads to cell death.
DISCUSSION
Treatment options in TNBC are limited to chemotherapy, radia-
tion, and surgery. The response of individual patients to these
intervention strategies is often unpredictable, incomplete, and
ephemeral. There is an urgent need to identify new therapeutic
entry points with associated predictive biomarkers to improve
long-term outcomes for this patient population. The molecular
classification of tumors into intrinsic subtypes presents an oppor-
tunity to determine if selective vulnerabilities exist among the dif-
ferent phenotypes within TNBC. By capitalizing on the faithful
recapitulation of tumor subtypes in patient-derived cell lines, we
find that SIK2 is selectively essential for survival particularly in the
claudin-low subtype. Notably, this is the first identification of a
molecular vulnerability aligned with the claudin-low disease,
which is less sensitive to first-line chemotherapeutic regimens
than other TNBC subtypes (7). Our findings may represent an
important first step in tailoring treatment to this groupof patients.
In particular, ARN-3230 is an emerging SIK2 inhibitor for use in
ovarian cancer patients that could be applied to the claudin-low
setting. It is important to note that the alignment of SIK2 sensi-
tivity was not uniform among the claudin-low cell lines tested.
Additional investigations into molecular biomarkers that predict
SIK2 sensitivity will be essential for more precisely identifying
responsive patients.
Our findings suggest that SIK2 restricts autophagic flux. Au-
tophagy has been implicated in both pro- and antitumorigenic
function. For example, autophagy can be essential for tumor cell
survival by limiting death due to hypoxia, inflammation, and che-
motherapy (35–38). Conversely, suppression of autophagy has
been unequivocally shown to limit tumorigenesis in mouse mod-
els (39–41). The contribution of autophagy to tumorigenesis is
likely dependent on many factors, including the disease site and
stage. Our findings suggest that autophagy is a tumor suppressor
mechanism in claudin-low breast cancer. This result is also sup-
ported by human clinical studies demonstrating that beclin-1, an
essential autophagy gene, is frequently lost in TNBC and corre-
lates with poor survival (30). Our studies, particularly with ATG
codepletion, suggest that the inhibition of SIK2 leads to an au-
tophagic cell death (42). Whether autophagy itself is directly exe-
cuting the cell death is unclear. It is possible that the unrestrained
autophagy is leading to autolysis in sensitive cells (43). Perhaps the
endoplasmic reticulum in SIK2-dependent cells is more easily de-
pleted, leading to a rapid loss of viability once high levels of au-
tophagy are activated. Alternatively, autophagy may be triggering
cell death processes, such as necrosis or apoptosis, and SIK2 is
required to prevent these mechanisms. Finally, activation of au-
tophagy could kill only certain sets of tumor cells through the
selective degradation of limiting substrates, including proteins or
organelles such asmitochondria. Perhaps inhibition of autophagy
is essential for maintenance of the mesenchymal and primordial
features of claudin-low tumors, without which these tumor cells
activate cell death programs. Reactivation of tumor suppressor
functions lost during transformation is a particularly difficult
therapeutic strategy. As we find that SIK2may restrain autophagy,
reinstating this antitumor function could be a feasible strategy
through small-molecule inhibition of SIK2.
SIK2 has been implicated in promoting gluconeogenesis in
liver and mitotic fidelity in ovarian and prostate cancers. In our
system, we found no evidence that SIK2 inhibition led to mitotic
defects (see Fig. S2 in the supplemental material). Furthermore,
inhibition of CRTCs had no impact on the SIK2 phenotype in
TNBC (not shown). Thus, our work, alongwith two prior reports,
presents a strong case that SIK2 represents a novel autophagic
regulatory pathway (18, 21). The molecular mechanisms that ac-
tivate SIK2 and its downstream substrates are poorly described
outside of gluconeogenesis. A recent exhaustive study in hepato-
cytes reported numerous putative phosphorylation events on
SIK2 following fasting/glucagon exposure; however, none of these
events led to a detectable alteration in intrinsic catalytic activity
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(31). Low-stearic-hindrance gatekeeper residues, such as SIKs, are
associated with higher basal kinase activity (27). Thus, it is possi-
ble that SIK2 activity undergoes negative regulation by upstream
kinases, as has been shown for PKA. Furthermore, the only well-
validated SIK substrates are CRTC1-3 and HDAC4 (12, 13, 44).
One report suggested that SIK2 resides on autophagic vesicles,
presenting the possibility that it directly phosphorylates key regu-
lators of vesicle formation. Taken together, our findings present a
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fresh phenotypic context to study SIK2 regulatory processes that
impinge on autophagy in both the normal and transformed states.
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